Business concepts,Businessman holding a pen pointing at a graph. picture there is graph in the background window.

Paratek Pharmaceuticals, Inc. [NASDAQ: PRTK] shares went higher by 2.00% from its previous closing of $3.00, now trading at the price of $3.06, also adding 0.06 points. Is PRTK stock a buy or should you stay away?

The stock had a rather active trading session with the latest closing, by far recording 1.09 million contracts. Compared to the average trading volume of PRTK shares, the company saw a far better performance. Moreover, the stock has a 32.19M float and a +4.44% run over in the last seven days. PRTK share price has been hovering between $7.39 and $2.66 lately, and is definitely worthy of attention.

Paratek Pharmaceuticals, Inc. [NASDAQ:PRTK]: Analyst Rating and Earnings

Its stock price has been found in the range of 2.66 to 7.39. This is compared to its latest closing price of $3.00.

Stay on the lookout for the next quarterly financial report – the company is expected to release the following results on Wed 26 Feb (In 80 Days).

Fundamental Analysis of Paratek Pharmaceuticals, Inc. [PRTK]

Now let’s turn to look at profitability: with a current Operating Margin for Paratek Pharmaceuticals, Inc. [PRTK] sitting at -607.87.

This company’s Return on Total Capital is -49.76, and its Return on Invested Capital has reached -37.80%. Its Return on Equity is -172.78, and its Return on Assets is -48.44. These metrics suggest that this Paratek Pharmaceuticals, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.

Turning to investigate this organization’s capital structure, Paratek Pharmaceuticals, Inc. [PRTK] has generated a Total Debt to Total Equity ratio of 481.23. Similarly, its Total Debt to Total Capital is 82.80, while its

Total Debt to Total Assets stands at 76.27. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is -9.47, and its Long-Term Debt to Total Capital is 481.23.

What about valuation? This company’s Enterprise Value to EBITDA is -0.78. The Enterprise Value to Sales for this firm is now 3.26, and its Total Debt to Enterprise Value stands at 1.64. Paratek Pharmaceuticals, Inc. [PRTK] has a Price to Book Ratio of 3.48.

Shifting the focus to workforce efficiency, Paratek Pharmaceuticals, Inc. [PRTK] earns $164,587 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 5.58 and its Total Asset Turnover is 0.07. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 14.41 and its Current Ratio is 14.41. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

Paratek Pharmaceuticals, Inc. [PRTK] has 32.65M shares outstanding, amounting to a total market cap of $99.91M. Its stock price has been found in the range of 2.66 to 7.39. At its current price, it has moved down by -58.59% from its 52-week high, and it has moved up 15.04% from its 52-week low.

This stock’s Beta value is currently 1.86, which indicates that it is 5.42% more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 44.09. This RSI score is good, suggesting this stock is neither overbought or oversold.

Conclusion: Is Paratek Pharmaceuticals, Inc. [PRTK] a Reliable Buy?

Shares of Paratek Pharmaceuticals, Inc. [PRTK], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.